These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 12534449)

  • 1. Time-dependent effect of statins on platelet function in hypercholesterolaemia.
    Puccetti L; Pasqui AL; Pastorelli M; Bova G; Cercignani M; Palazzuoli A; Angori P; Auteri A; Bruni F
    Eur J Clin Invest; 2002 Dec; 32(12):901-8. PubMed ID: 12534449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
    Plans-Rubió P
    Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atorvastatin reduces platelet-oxidized-LDL receptor expression in hypercholesterolaemic patients.
    Puccetti L; Sawamura T; Pasqui AL; Pastorelli M; Auteri A; Bruni F
    Eur J Clin Invest; 2005 Jan; 35(1):47-51. PubMed ID: 15638819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of diet and treatment with statins on platelet-dependent thrombin generation in hypercholesterolemic subjects.
    Puccetti L; Bruni F; Bova G; Cercignani M; Palazzuoli A; Console E; Auteri A; Pasqui AL
    Nutr Metab Cardiovasc Dis; 2001 Dec; 11(6):378-87. PubMed ID: 12055702
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An economic analysis of the Atorvastatin Comparative Cholesterol Efficacy and Safety Study (ACCESS).
    Smith DG; McBurney CR
    Pharmacoeconomics; 2003; 21 Suppl 1():13-23. PubMed ID: 12648031
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different effect of statins on platelet oxidized-LDL receptor (CD36 and LOX-1) expression in hypercholesterolemic subjects.
    Bruni F; Pasqui AL; Pastorelli M; Bova G; Cercignani M; Palazzuoli A; Sawamura T; Gioffre WR; Auteri A; Puccetti L
    Clin Appl Thromb Hemost; 2005 Oct; 11(4):417-28. PubMed ID: 16244767
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A model to assess the cost effectiveness of statins in achieving the UK National Service Framework target cholesterol levels.
    Wilson K; Marriott J; Fuller S; Lacey L; Gillen D
    Pharmacoeconomics; 2003; 21 Suppl 1():1-11. PubMed ID: 12648030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study).
    Jones P; Kafonek S; Laurora I; Hunninghake D
    Am J Cardiol; 1998 Mar; 81(5):582-7. PubMed ID: 9514454
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects.
    Schaefer EJ; McNamara JR; Tayler T; Daly JA; Gleason JL; Seman LJ; Ferrari A; Rubenstein JJ
    Am J Cardiol; 2004 Jan; 93(1):31-9. PubMed ID: 14697462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins.
    Andrews TC; Ballantyne CM; Hsia JA; Kramer JH
    Am J Med; 2001 Aug; 111(3):185-91. PubMed ID: 11530028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Platelet hyperactivity after statin treatment discontinuation.
    Puccetti L; Pasqui AL; Pastorelli M; Bova G; Di Renzo M; Leo A; Cercignani M; Palazzuoli A; Auteri A; Bruni F
    Thromb Haemost; 2003 Sep; 90(3):476-82. PubMed ID: 12958617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of an indirect effect model to describe the LDL cholesterol-lowering effect by statins in hypercholesterolaemic patients.
    Faltaos DW; Urien S; Carreau V; Chauvenet M; Hulot JS; Giral P; Bruckert E; Lechat P
    Fundam Clin Pharmacol; 2006 Jun; 20(3):321-30. PubMed ID: 16671968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Atorvastatin induces associated reductions in platelet P-selectin, oxidized low-density lipoprotein, and interleukin-6 in patients with coronary artery diseases.
    Oka H; Ikeda S; Koga S; Miyahara Y; Kohno S
    Heart Vessels; 2008 Jul; 23(4):249-56. PubMed ID: 18649055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).
    Jones PH; Davidson MH; Stein EA; Bays HE; McKenney JM; Miller E; Cain VA; Blasetto JW;
    Am J Cardiol; 2003 Jul; 92(2):152-60. PubMed ID: 12860216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care.
    Harley CR; Gandhi SK; Heien H; McDonough K; Nelson SP
    Expert Opin Pharmacother; 2008 Apr; 9(5):669-76. PubMed ID: 18345946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lowering effects of four different statins on serum triglyceride level.
    Branchi A; Fiorenza AM; Rovellini A; Torri A; Muzio F; Macor S; Sommariva D
    Eur J Clin Pharmacol; 1999 Sep; 55(7):499-502. PubMed ID: 10501818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The ability of statins to protect low density lipoprotein from oxidation in hypercholesterolemic patients.
    Thallinger C; Urbauer E; Lackner E; Graselli U; Kostner K; Wolzt M; Joukhadar C
    Int J Clin Pharmacol Ther; 2005 Dec; 43(12):551-7. PubMed ID: 16372516
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 3'UTR/T polymorphism of lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) is associated with modified anti-platelet activity of atorvastatin in hypercholesterolemic subjects.
    Puccetti L; Pasqui AL; Pastorelli M; Ciani F; Palazzuoli A; Gioffrè W; Auteri A; Bruni F
    Atherosclerosis; 2005 Dec; 183(2):322-8. PubMed ID: 16285995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced platelet aggregation after fluvastatin therapy is associated with altered platelet lipid composition and drug binding to the platelets.
    Osamah H; Mira R; Sorina S; Shlomo K; Michael A
    Br J Clin Pharmacol; 1997 Jul; 44(1):77-83. PubMed ID: 9241100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.